(Total Views: 320)
Posted On: 07/01/2025 1:45:39 PM
Post# of 154874
DSP107 + atezolizumab in 3L MSS crc was able to get an oral presentation at ASCO last month.
"The median OS from the efficacy-evaluable patients who received DSP107 monotherapy (n=19) and combination therapy with atezolizumab (n=21) has not been reached, but currently (May 2025 cutoff) stands at 8.1 and 17 months, respectively. Disease control was demonstrated in 21% (monotherapy) and 62% (combination) of evaluable patients including a patient who achieved a complete response (> 2.5 years) and a patient with a deep (86% target lesion reduction) and durable (> 16 months) confirmed partial response and disappearance of pulmonary and hepatic metastases."
Can't wait for our results and oral presentations, getting the word out on leronlimab.
https://www.prnewswire.com/news-releases/kahr...70389.html
"The median OS from the efficacy-evaluable patients who received DSP107 monotherapy (n=19) and combination therapy with atezolizumab (n=21) has not been reached, but currently (May 2025 cutoff) stands at 8.1 and 17 months, respectively. Disease control was demonstrated in 21% (monotherapy) and 62% (combination) of evaluable patients including a patient who achieved a complete response (> 2.5 years) and a patient with a deep (86% target lesion reduction) and durable (> 16 months) confirmed partial response and disappearance of pulmonary and hepatic metastases."
Can't wait for our results and oral presentations, getting the word out on leronlimab.
https://www.prnewswire.com/news-releases/kahr...70389.html
(3)
(0)
